“Risk of cytomegalovirus reactivation in patients with immune-mediated inflammatory diseases undergoing biologic treatment: a real matter?”, Reumatismo, vol. 68, no. 3, pp. 144–147, Dec. 2016, doi: 10.4081/reumatismo.2016.897.